Quentis Therapeutics, Inc. — Form D
Quentis Therapeutics, Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2018-03-01. The offering totals $47.9M, of which $19.7M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2018-03-01
- Form: D
- Accession: 0001676135-18-000003
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $47.9M
- Amount sold: $19.7M
- Remaining: $28.2M
- Investors: 16
- Date of first sale: 2018-02-15
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-306751
Issuer
- Name: Quentis Therapeutics, Inc.
- CIK: 0001676135
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 430 E 29th Street, NEW YORK, NY, 10016
- Phone: (646) 440-9248
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Michael Aberman | Director | Cambridge, MA |
| Michael Foley | Director | Apex, NC |
| Carlo Rizzuto | Director | Littleton, CO |
| Amy Schulman | Director | Cambridge, MA |
| Michael Aberman | Executive Officer | Cambridge, MA |
| Carlo Rizzuto | Executive Officer | Littleton, CO |
| Joseph P Vacca, Ph.D | Executive Officer | New York, NY |
| B. Finn Peter | Executive Officer | Boston, MA |
| Michael Finn Foley, Ph.D. | Director | New York, NY |
Other filings by this issuer (1)
More